[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335638-105":59,"doc-detail-335638-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","two-in-one-nanoparticle-platform-induces-a-strong-therapeutic-effect-of-targeted-therapies-in-p-selectinexpressing-cancers","Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers","","Cancer combination therapies aim to strengthen antitumor activity through synergistic or additive drug ratios, yet co-administering small molecules is difficult because different drugs differ in pharmacokinetics and tumor penetration, which can narrow the therapeutic window. A PLGA-PEG nanoparticle platform was developed to enable codelivery of synergistic ratios, increasing the fraction of the injected dose reaching tumors. To address extravasation-dependent variability, the platform was modified with sulfates for active P-selectin targeting. Three-dimensional in vitro and in vivo models show enhanced accumulation in P-selectin–expressing BRAF-mutated melanomas and BRCA-mutated breast cancers, improving efficacy and safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/two-in-one-nanoparticle-platform-induces-a-strong-therapeutic-effect-of-targeted-therapies-in-p-selectinexpressing-cancers/335638/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/two-in-one-nanoparticle-platform-induces-a-strong-therapeutic-effect-of-targeted-therapies-in-p-selectinexpressing-cancers/335638.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are nanoparticle platforms needed for combination cancer therapies?","Question",{"text":112,"@type":113},"Different drugs can have distinct pharmacokinetic profiles and tumor penetration abilities, which limits synergy and makes it hard to optimize the therapeutic window. Nanoparticle platforms are designed to enhance codelivery to improve therapeutic benefit.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the two-in-one (PLGA-PEG) nanoparticle platform improve therapy?",{"text":117,"@type":113},"It enables codelivery of synergistic drug ratios in a single nanoparticle and increases the percentage of the injected dose that reaches the tumor.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of sulfates and P-selectin targeting in this study?",{"text":121,"@type":113},"The platform is modified with multivalent sulfates to actively target P-selectin–expressing cancers, overcoming limitations of passive, extravasation-dependent tumor accumulation. This leads to enhanced accumulation in relevant 3D cancer models and improved in vivo efficacy and safety.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335638,1791588148,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","CANCER  \nTwo-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in  \nP-selectin–expressing cancers  \nShani Koshrovski-Michael1, Daniel Rodriguez Ajamil1, Pradip Dey1,2, Ron Kleiner1, ShaharTevet3,4,5,6, Yana Epshtein1, Marina Green Buzhor1, Rami Khoury1, Sabina Pozzi1, Gal Shenbach-Koltin1, EilamYeini1, Laura Woythe7, Rachel Blau1, Anna Scomparin8, Iris Barshack9,10, Helena F. Florindo11, Shlomi Lazar12, Lorenzo Albertazzi7,  \nRoey J. Amir3,4,5,6, Ronit Satchi-Fainaro1,5,13*  \nCombined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their therapeutic efficacy. To circumvent this, poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–based nanoparticles were developed as a platform for the codelivery of synergistic drug ratios, improving therapeutic efficacy by increasing the percentage of injected dose reaching the tumor. Nonetheless, extravasation-dependent tumor accumulation is susceptible to variations in tumor vasculature; therefore, PLGAPEG was modified with sulfates to actively target P-selectin–expressing cancers. Here, we show the potential of our platform in unique three-dimensional (3D) in vitro and in vivo models. The P-selectin–targeted nanoparticles showed enhanced accumulation in 3D spheroids and tissues of P-selectin–expressing BRAF-mutated melanomasand BRCA-mutated breast cancers, resulting in superior in vivo efficacy and safety. This nanoplatform could advance the codelivery of a plethora of anticancer drug combinations to various P-selectin–expressing tumors.  \ncopyright © 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. Distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nCombination treatment is a fundamental principle in cancer therapy aimed at reducing the required dose of each drug via the enhancement of efficacy through synergistic or additive activity. However, combining drugs may increase the risk of side effects, as each drug may induce diverse adverse events. Moreover, different drugs may display distinct physicochemical properties, thereby presenting substantially varied pharmacokinetics, limiting the potential synergistic effect and making it difficult to optimize the therapeutic window of such drugs combinations. Therefore, thereis a need for platforms capable of enhancing the codelivery and maximizing therapeutic benefits, thus advancing the field of drug combinations for cancer treatment strategies.  \nHere, we propose the use of a poly(lactic-co-glycolic acid)– poly(ethylene glycol) (PLGA-PEG)–based nanosystem as a platform  \n1Department of Physiology and Pharmacology, Faculty of Medicine, tel versity, tel Aviv 6997801, israel. 2Department of chemistry, Siksha  \nAviv UniBhavana,  \nvisva-Bharati University, Santiniketan, West Bengal 731235, india. 3the center for Physics and chemistry of living Systems, tel Aviv University, tel Aviv 6997801, israel. 4Department of Organic chemistry, School of chemistry, Faculty of exact Sciences, tel Aviv University, tel Aviv 6997801, israel. 5tel Aviv University center for nanoscience and nanotechnology, tel Aviv University, tel Aviv 6997801, israel. 6ADAMA center for novel Delivery Systems in crop Protection, tel Aviv University, tel Aviv 6997801, israel. 7Department of Biomedical engineering, institute for complex Molecular Systems (icMS), eindhoven University of technology (tU/e), 5612AZ eindhoven, netherlands. 8Department of Drug Science and technology, University of turin, turin 10125, italy. 9Department of Pathology, Sheba Medical center, tel hashomer, Ramat-Gan 52621, israel. 10Department of Pathology, Faculty of Medicine, tel Aviv University, tel Aviv 6997801, israel. 11","cbCaisDyUpL7yWsO","https://ap.wps.com/l/cbCaisDyUpL7yWsO","pdf",10316689,25,"English","# Introduction\n## Rationale for combination therapy in cancer\n## Challenges with co-delivering multiple drugs\n## PLGA-PEG two-in-one nanoparticle platform\n## Active targeting via P-selectin-modified sulfates","[{\"question\":\"Why are nanoparticle platforms needed for combination cancer therapies?\",\"answer\":\"Different drugs can have distinct pharmacokinetic profiles and tumor penetration abilities, which limits synergy and makes it hard to optimize the therapeutic window. Nanoparticle platforms are designed to enhance codelivery to improve therapeutic benefit.\"},{\"question\":\"How does the two-in-one (PLGA-PEG) nanoparticle platform improve therapy?\",\"answer\":\"It enables codelivery of synergistic drug ratios in a single nanoparticle and increases the percentage of the injected dose that reaches the tumor.\"},{\"question\":\"What is the role of sulfates and P-selectin targeting in this study?\",\"answer\":\"The platform is modified with multivalent sulfates to actively target P-selectin–expressing cancers, overcoming limitations of passive, extravasation-dependent tumor accumulation. This leads to enhanced accumulation in relevant 3D cancer models and improved in vivo efficacy and safety.\"}]","Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers | PDF",1790011759,63]